Meetings - The ASCO Post

By The ASCO Post Staff / ESMO Congress 2025

Domenica Lorusso, MD, PhD, on Platinum-Resistant Ovarian Cancer: Relacorilant and Nab-Paclitaxel in Pretreated Patients

Domenica Lorusso, MD, PhD, of Humanitas University, discusses results of a preplanned analysis from the ROSELLA trial. In the phase III study, the addition of relacorilant to nab-paclitaxel significan...

gynecologic cancers

By The ASCO Post Staff / ESMO Congress 2025

Andrew R. Clamp, MD, PhD, on High-Risk Ovarian Cancer: Weekly Dose-Dense and Every-3-Week Chemotherapy Plus Bevacizumab

Andrew R. Clamp, MD, PhD, of The Christie NHS Foundation Trust, reviews results of the phase III ICON8B trial, which found that in patients with high-risk stage III to IV epithelial ovarian cancer, th...

gynecologic cancers

By The ASCO Post Staff / ESMO Congress 2025

Emese Zsiros, MD, PhD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel

Emese Zsiros, MD, PhD, of Roswell Park Comprehensive Cancer Center, reviews results from the randomized, double-blind, phase III ENGOT-ov65/KEYNOTE-B96 trial. According to the study investigators, “Pe...

ESMO Congress 2025

Domenica Lorusso, MD, PhD, on Platinum-Resistant Ovarian Cancer: Relacorilant and Nab-Paclitaxel in Pretreated Patients

Andrew R. Clamp, MD, PhD, on High-Risk Ovarian Cancer: Weekly Dose-Dense and Every-3-Week Chemotherapy Plus Bevacizumab

Emese Zsiros, MD, PhD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel

Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma

In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL

Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma

Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer

Are Food Preservatives Linked to Increased Cancer Risk